Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB-Cell Maturation Antigen
Dr. Beata Holkova, MD
NPI1871751727
- Medicare services, 2018
- 261
- Part D claims, 2018
- 54
- Publications
- 17
- Clinical trials
- 6
- Industry payments
- $4,548
- Practice address
- 9109 Stony Point Dr, Richmond, VA 23235
- Practice phone
- Call (804) 828-7999
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Find Dr. Holkova's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Beata Holkova is a hematologist and oncologist in Richmond, Virginia
Dr. Holkova practices in Richmond, Virginia.
Dr. Holkova's NPI, 1871751727, was assigned on May 28, 2008. Dr. Holkova holds Virginia license 0101243924.
NPI and contact details
- NPI
- 1871751727NPI Registry (opens in a new tab)
- NPI enumeration date
- May 28, 2008
- NPI status
- Active
- Practice phone
- (804) 828-7999
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
Sources: NPPES NPI Registry (CMS); and Dmand AI Professional Profile Data
Dr. Beata Holkova's practice address is in Richmond, Virginia
Dr. Holkova's practice address in the NPI Registry is 9109 Stony Point Dr, Richmond, VA 23235, in Chesterfield County. The practice phone is (804) 828-7999.
- NPI Registry address9109 Stony Point Dr, Richmond, VA 23235 · Chesterfield CountyPhone(804) 828-7999
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dmand AI tracks the EHR system at Dr. Beata Holkova's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Holkova practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Dr. Holkova's practice | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Holkova practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Beata Holkova is one of 297 hematologists and oncologists in Virginia
Hematology and oncology is Dr. Holkova's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Holkova's licenses on file in 2 states: Virginia and Michigan.
Specialties and state licenses
- Hematology and oncology, VirginiaPrimary
- Legal medicine, Michigan
Hematologists and oncologists near Dr. Holkova
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Beata Holkova billed Medicare for 261 services in 2018
CMS data shows 261 Medicare services from Dr. Holkova across 4 procedure codes in 2018. Medicare paid $21,502 for them. Every service was in a facility, such as a hospital, rather than an office.
Medicare services, 2018261
Paid by Medicare$21,502
Procedure codes4
Dr. Holkova's Medicare services by type, 2017 to 2018
- 2017
- 2018
- Office and hospital visits
- 2017: 2412018: 2618%
Dr. Holkova compared with the Virginia median for hematologists and oncologists, 2018
- Dr. Holkova
- Virginia median
- Medicare services
- 261vs 3,51493% below
- Part D claims
- 54vs 45288% below
Medians across 275 hematologists and oncologists in Virginia with Dmand AI profiles that report each measure.
Dr. Holkova's most billed Medicare procedure codes, 2018
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Holkova?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Holkova and other hematologists and oncologists in Virginia.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Beata Holkova's patients have a median age of 71
Across all payers, Dmand AI patient panel data puts Dr. Holkova's median patient age at 71, with 0% women.
Dr. Holkova's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 71
Patient panel by sex, all payers
- Women0%
- Men100%
Source: Dmand AI Patient Panel Data
Dr. Beata Holkova wrote 54 Medicare Part D claims in 2018
In 2018, Dr. Holkova wrote 54 Medicare Part D claims. Every claim was for a generic drug. They cover 2 drugs, with $765 in total drug cost. In 2017, CMS named 124 claims across 5 drugs.
Part D claims, 201854
Drugs named by CMS2
Total drug cost$765
Dr. Holkova's most prescribed drugs by claims, 2018
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2017 to 2018
- 2017
- 2018
- Claims for drugs CMS names
- 2017: 1242018: 5456%
Drugs named by CMS: 2 in 2018, 5 in 2017.
Source: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026
For MedTech and pharma teams
Find hematologists and oncologists like Dr. Holkova by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Beata Holkova has 17 publications on record
Dmand AI links 17 papers to Dr. Holkova, published from 2011 to 2021. 2014 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Bortezomib and Boronic Acids. Dr. Holkova has published most often in Clin Cancer Res. Dr. Holkova's most frequent co-authors are Victor Youssef Yazbeck, MD, Prithviraj Bose, MD and Amy S. Kimball, MD, PhD.
Papers17
Years published2011 to 2021
Dr. Holkova's papers by year, 2012 to 2021
Topics Dr. Holkova writes about most
- Antineoplastic Combined Chemotherapy Protocols
- Bortezomib
- Boronic Acids
- Hydroxamic Acids
- Multiple Myeloma
- Pyrazines
- Antineoplastic Agents
- Cell Line, Tumor
Dr. Holkova's most frequent co-authors
- Victor Youssef Yazbeck, MD5 shared papers
- Prithviraj Bose, MD3 shared papers
- Amy S. Kimball, MD, PhD2 shared papers
Recent publications by Dr. Holkova
Antineoplastic Combined Chemotherapy ProtocolsBortezomibHydroxamic Acids
Antineoplastic Combined Chemotherapy ProtocolsBortezomibDepsipeptides
See who Dr. Holkova researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Holkova works with, so you can find a warm path to the right hematologists and oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Beata Holkova has worked on 6 clinical trials
Dmand AI links Dr. Holkova to 6 clinical trials, 4 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse, Multiple Myeloma and Blood Protein Disorders. Alliance for Clinical Trials in Oncology sponsors the most, 2.
Clinical trials with Dr. Holkova by phase
- NonePhase 1: no trials
- 1Phase 1/2: 1 trial
- 4Phase 2: 4 trials
- 1Phase 3: 1 trial
- NonePhase 4: no trials
Conditions in Dr. Holkova's trials
- Lymphoma, Large B-Cell, Diffuse
- Multiple Myeloma
- Blood Protein Disorders
- Lymphoma, B-Cell
- Hodgkin Disease
Investigators on the most trials with Dr. Holkova
- Julian Ruffin Sprague, MD3 shared trials
- Nancy Lee Bartlett, MD2 shared trials
- Donald James Brooks, MD2 shared trials
Recent clinical trials with Dr. Holkova
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (opens in a new tab)
TerminatedPhase 1/2
Multiple MyelomaBlood Protein DisordersDexamethasoneIbrutinibPomalidomide
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma (opens in a new tab)
Active, not recruitingPhase 3
Multiple MyelomaBlood Protein DisordersBortezomibCarfilzomibDexamethasone
Lymphoma, Large B-Cell, DiffuseLymphoma, B-CellBrentuximab vedotinCyclophosphamideDoxorubicin
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) (opens in a new tab)
CompletedPhase 2
Lymphoma, T-Cell, PeripheralLymphoma, T-CellBrentuximab vedotinBendamustineDacarbazine
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (opens in a new tab)
Active, not recruitingPhase 2
Lymphoma, Large B-Cell, DiffuseLymphoma, B-CellCarmustineCytarabineEtoposide
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Beata Holkova received $4,548 in industry payments from 2016 to 2018
CMS Open Payments shows 12 general payments to Dr. Holkova from 5 drug and device companies from 2016 to 2018. Consulting fees make up the largest share, 58% of the total. Celgene Corporation paid the most, $2,640.
General payments to Dr. Holkova by program year, 2016 to 2018
General payments to Dr. Holkova by kind, 2016 to 2018
$4.5Kin total
- Consulting fees$2,64058%
- Travel and lodging$1,64836%
- Food and beverage$2365%
- Education$251%
Companies that paid Dr. Holkova the most, 2016 to 2018
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. Beata Holkova's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel Data |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Beata Holkova
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Beata Holkova's NPI number?
Dr. Beata Holkova's NPI number is 1871751727. It was assigned on May 28, 2008, and it is active in the NPI Registry.
What kind of doctor is Dr. Beata Holkova?
Dr. Beata Holkova is a hematologist and oncologist in Richmond, Virginia. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. Beata Holkova practice?
Dr. Holkova practices at 9109 Stony Point Dr, Richmond, VA 23235.
What is Dr. Beata Holkova's office phone number?
The practice phone on file for Dr. Holkova is (804) 828-7999.
What is Dr. Beata Holkova's medical license number?
Dr. Holkova holds Virginia license 0101243924, one of the licenses on file in 2 states.
Which states has Dr. Beata Holkova been licensed in?
Dmand AI has state licenses on file for Dr. Holkova in Virginia and Michigan.
Does Dr. Beata Holkova accept Medicare?
Yes. CMS data shows Dr. Holkova billed Medicare for 261 services in 2018.
What services does Dr. Beata Holkova bill to Medicare?
In 2018, Dr. Holkova's most billed Medicare services were hospital inpatient care (99233), office visit, established patient (99215) and office visit, established patient (99214).
What drugs does Dr. Beata Holkova prescribe most?
In 2018 Medicare Part D data, Dr. Holkova's most prescribed drugs by claims were Acyclovir and Dexamethasone.
Has Dr. Beata Holkova received payments from drug or device companies?
CMS Open Payments shows $4,548 in general payments to Dr. Holkova from 5 companies from 2016 to 2018. The largest total came from Celgene Corporation.
Show 3 more questionsShow fewer questions
How long has Dr. Beata Holkova been practicing?
Dr. Holkova's NPI was assigned in 2008.
Does Dr. Beata Holkova do research?
Dmand AI links 17 publications to Dr. Holkova, published from 2011 to 2021. Dr. Holkova has worked on 6 clinical trials.
Who does Dr. Beata Holkova publish with?
Dr. Holkova's most frequent co-authors are Victor Youssef Yazbeck, MD (5 shared papers), Prithviraj Bose, MD (3 shared papers) and Amy S. Kimball, MD, PhD (2 shared papers).
Selling to hematology and oncology practices?
See hematologists and oncologists in Virginia by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card